Skip to main content

Table 2 Relation between LRFS, EZH2 and clinicopathologic factors in patients who received radiation

From: EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer

Prognostic factors Number of patients/number of deaths 5-year LRFS (95% CI) P value
Age of diagnosis (N = 62)
 ≥ 45 40/12 72.7 (54.8 – 84.8) 0.43
 < 45 22/7 60.9 (33.9 – 79.6)
Race (N = 59)
 Non-Hispanic White 48/13 74.3 (58.4 – 85.1) 0.36
 All others 11/4 56.1 (19.5 – 81.5)
Lymph node status (N = 60)
 Negative 7/2 83.3 (27.3 – 97.4) 0.79
 Positive 53/16 67.3 (51.3 – 79.2)
Histologic type (N = 62)
 Ductal 54/17 68.7 (53.2 – 80.1) 0.72
 Others 8/2 75.0 (31.5 – 93.1)
Lymphovascular invasion (N = 56)
 No 9/0 100 0.07
 Yes 47/16 66.8 (48.9 – 78.5)
ER expression (N = 61)
 Negative 34/16 44.4 (24.1 – 62.9) 0.001
 Positive 27/3 92.3 (72.6 – 98.0)
PR expression (N = 61)
 Negative 42/16 58.4 (39.9 – 73.0) 0.025
 Positive 19/3 88.2 (60.2 – 96.9)
HER2 expression (N = 61)
 Negative 39/13 68.5 (49.9 – 81.2) 0.81
 Positive 22/6 70.0 (39.1 – 84.3)
Triple-negative status (N = 61)
 No 45/9 82.6 (66.6 – 91.4) 0.0001
 Yes 16/10 25.7 ( 6.4 – 51.0)
Radiation type (N = 62)
 Postoperative 55/17 69.4 (54.0 – 80.5) 0.73
 Preoperative 7/2 64.3 (15.2 – 90.2)
BID radiation (N = 48)
 No 10/3 80.0 (40.9 – 94.6) 0.21
 Yes 38/14 58.0 ( 38.9 – 73.0)
EZH2 (N = 62)
 No 17/1 92.8 (59.1 – 98.9) 0.01
 Yes 45/18 59.2 (41.5 – 73.1)